Table 1.
Repositioning potential and known therapeutic targets by phenotype.
| PH | ≠ TT | TI | RN | RTT | NTT | NV | RN |
|---|---|---|---|---|---|---|---|
| T2D | 84 | 0.29 | 5th | 7 | 77 | 0.92 | 5th |
| T1D | 97 | 0.27 | 6th | 2 | 95 | 0.98 | 2nd |
| RA | 77 | 0.38 | 2nd | 6 | 71 | 0.92 | 5th |
| HT | 78 | 0.35 | 4th | 5 | 73 | 0.94 | 4th |
| BD | 59 | 0.27 | 6th | 1 | 58 | 0.98 | 2nd |
| CD | 135 | 0.36 | 3rd | 0 | 135 | 1.00 | 1st |
| CAD | 102 | 0.39 | 1st | 4 | 98 | 0.96 | 3rd |
Abbreviations - PH - Phenotypes; ≠TT - Number of Therapeutic Targets; TI - Targetability Index; NTT - Novel Therapeutic Targets; RTT - Replicated Therapeutic Targets; NV - Novelty; RN - Rank; T2D - Type 2 Diabetes; BD - Bipolar Disorder; CD - Crohn's Disease; HT - Hypertension; T1D - Type 1 Diabetes; CAD - Coronary Artery Disease; RA - Rheumatoid Arthritis.
Description of therapeutic targets and novel therapeutic targets. Total 452 unique therapeutic targets and total 428 unique novel therapeutic targets obtained for seven complex diseas